原发性肝癌血管性介入治疗的现状

doi:10.3969/j.issn.1672-5069.2015.02.001

实用肝脏病杂志 ›› 2015, Vol. 18 ›› Issue (3): 225-227.doi: 10.3969/j.issn.1672-5069.2015.02.001

• 述评 • 下一篇

原发性肝癌血管性介入治疗的现状

陈东风, 孙文静

400042 重庆市第三军医大学大坪医院野战外科研究所消化内科

收稿日期:2015-02-10 出版日期:2015-05-10 发布日期:2016-02-19
作者简介:陈东风,男,51岁,第三军医大学大坪医院野战外科研究所消化内科主任,教授,博士生导师。现任中华医学会消化病学分会常委,重庆市医学会消化病学分会主任委员。E-mail: chendf1981@126.com

Current status on vascular interventional treatment of primary liver cancer

Chen Dongfeng, Sun Wenjing

Department of Gastroenterology,Research Institute of Surgery,Daping Hospital,Third Military Medical University,Chongqing 400042

Received:2015-02-10 Online:2015-05-10 Published:2016-02-19

摘要/Abstract

关键词: 原发性肝癌, 介入治疗, 经肝动脉化疗栓塞术

Key words: Primary liver cancer, Interventional treatment, Transarterial chemoembolization

陈东风, 孙文静. 原发性肝癌血管性介入治疗的现状[J]. 实用肝脏病杂志, 2015, 18(3): 225-227.

Chen Dongfeng, Sun Wenjing. Current status on vascular interventional treatment of primary liver cancer[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(3): 225-227.

[1] 鲁东,吕维富. 肝癌血供研究进展. 中国介入影像与治疗学, 2007,4（3）:227-231.
[2] Kim SH,Kamaya A,Willmann JK. CT perfusion of the liver: principles and applications in oncology. Radiology,2014,272（2）:322-344.
[3] Cheng LF,Ma KF,Fan WC,et al. Hepatocellular carcinoma with extrahepatic collateral arterial supply. J Med Imaging Radiat Oncol,2010,54（1）:26-34.
[4] Rahbari NN,Mehrabi A,Mollberg NM,et al. Hepatocellular carcinoma:current management and perspectives for the future. Ann Surg,2011,253（3）:453-469.
[5] Lo C,Ngan H,Tso W. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology,2002,35（5）:1164-1171.
[6] Llovet J,Real M,Montana X. Arterial embolisation or chemoembolisation vs. symptomatic treatment in patients with unresectable hepatocellular carcinoma:a randomised controlled trial. Lancet,2002,359（9319）:1734-1739.
[7] Takayasu K,Arii S,Ikai I. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology,2006,131（2）:461-469.
[8] Zhao Y,Cai G,Zhou L,et al. Transarterial chemoembolization in hepatocellular carcinoma with vascular in invasion or extrahepatic metastasis:A systematic review. Asia Pac J Clin Oncol, 2013,9（4）:357-364.
[9] Talenfeld AD,Sista AK,Madoff DC. Transarterial therapies for primary liver tumors. Surg Oncol Clin N Am,2014,23（2）: 323-351.
[10] Bordoni A,Cerny A,Bihl F,et al. Survival of hepatocellular carcinoma patients is significantly improving:a population-based study from southern Switzerland. Cancer Epidemiol,2014,38（6）:679-685.
[11] Cabibbo G,Maida M,Genco C,et al. Natural history of untreatable hepatocellular carcinoma:A retrospective cohort study. World J Hepatol,2012,4（9）:256-261.
[12] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2010年版）. 实用肝脏病杂志,2011,14（2）：81-89.
[13] Lao XM, Luo G,Ye LT,et al. Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma. Liver Int, 2013,33（4）:595-604.
[14] 葛茜,吴宇旋. 营养干预对原发性肝癌介入治疗患者效果评价. 实用预防医学,2009,16（3）:828-830.
[15] Dhanasekaran R,Limaye A,Cabrera R. Hepatocellular carcinoma:current trends in worldwide epidemiology,risk factors,diagnosis,and therapeutics. Hepat Med,2012,4:19-37.
[16] 张成武,赵大建,胡智明,等. 原发性肝癌经肝动脉栓塞化疗术后预后指标的多因素分析. 肝胆胰外科杂志,2007,19（6）: 376-379.
[17] Eswaran SL,Pierce K,Weaver F,et al. Transarterial chemoembolization for HCC in patients with extensive liver transplantation waiting times. Angiology,2012,63（3）:206-212.
[18] Yoo DJ,Kim KM,Jin YJ,et al. Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma:does transarterial chemoembolization improve survival in these patients J Gastroenterol Hepatol, 2011,26（1）:145-154.
[19] Chung GE,Lee JH,Kim HY,et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology,2011,258（2）:627-634.
[20] Jeon SH,Park KS,Kim YH,et al. Incidence and risk factors of acute hepatic failure after transcatheter arterial embolization for hepatocellular carcinoma. Korean J Gastroenterol,2007,50（3）: 176-182.

原发性肝癌血管性介入治疗的现状

Current status on vascular interventional treatment of primary liver cancer

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	鲍应军, 任伟新. 门静脉血栓介入治疗研究进展[J]. 实用肝脏病杂志, 2019, 22(6): 768-769.
[2]	邢昊, 韩骏, 杨田. 应用血清PIVKA-II诊断肝细胞癌研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 934-937.
[3]	刘杏, 赵树立, 张殿隆. 七氟烷吸入时机对肝脏部分切除术患者肝脏缺血再灌注损伤的影响*[J]. 实用肝脏病杂志, 2019, 22(5): 728-731.
[4]	崔发强, 李涛, 王铮, 陈青. 原发性肝癌患者外周血KRAS基因水平及其对西妥昔单克隆抗体治疗疗效的影响[J]. 实用肝脏病杂志, 2019, 22(4): 565-568.
[5]	赵晓光, 史玉洁. 应用还原型谷胱甘肽预防处理接受TACE治疗的中晚期原发性肝癌患者对肝功能的影响[J]. 实用肝脏病杂志, 2019, 22(3): 425-428.
[6]	李克田,沈明格,王凤荣,胡春荣,曹玉杰,芦鹏. 血糖水平对原发性肝癌患者¹⁸F-FDG摄取和PET/CT检查图像质量的影响研究^*[J]. 实用肝脏病杂志, 2019, 22(2): 256-259.
[7]	王秀清,马艳君,詹晋莉. 肝动脉化疗栓塞术联合超声引导下微波消融术治疗特殊部位原发性肝癌患者疗效及安全性分析 ^*[J]. 实用肝脏病杂志, 2019, 22(2): 260-263.
[8]	王翠晓, 高静. 血清高尔基蛋白73、甲胎蛋白异质体3、甲胎蛋白和α-L-岩藻糖苷酶水平诊断原发性肝癌的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(1): 113-116.
[9]	陈向, 汪宝林, 吴琛, 唐劲草, 张弛, 褚朝顺. 动脉灌注化疗栓塞联合放射粒子植入治疗原发性肝癌患者疗效及其对肝组织TRF1和TRF2表达的影响^*[J]. 实用肝脏病杂志, 2019, 22(1): 121-124.
[10]	闫书鸣, 王建国, 李泽信, 游焜, 王亮, 郭鹏威. 门冬氨酸鸟氨酸治疗肝癌切除术患者对肝脏缺血再灌注损伤的保护作用研究^*[J]. 实用肝脏病杂志, 2018, 21(6): 932-935.
[11]	汪华, 赵亚宁. 索拉菲尼治疗进展期原发性肝癌患者有效性及安全性研究^*[J]. 实用肝脏病杂志, 2018, 21(6): 936-939.
[12]	杨学民, 李朝路, 李兆阳. microRNA194过表达抑制荷瘤小鼠肝癌细胞生长的实验研究^*[J]. 实用肝脏病杂志, 2018, 21(5): 705-708.
[13]	郭振宁. 超声造影诊断微小原发性肝癌患者临床价值研究[J]. 实用肝脏病杂志, 2018, 21(5): 741-744.
[14]	伍家彬, 谢晓海. 丙泊酚对肝部分切除术治疗的原发性肝癌患者外周血淋巴细胞亚群和血清肿瘤相关标志物水平的影响[J]. 实用肝脏病杂志, 2018, 21(5): 745-748.
[15]	王全晖, 张元浩, 袁守信, 乔师师. 腹腔镜下肝部分切除术治疗原发性肝癌患者外周血T淋巴细胞亚群和血清细胞因子水平的变化^*[J]. 实用肝脏病杂志, 2018, 21(5): 753-756.